Intas Pharmaceuticals acquires Actavis UK & Ireland generics businesses from Teva
Transaction is part of the European Commission’s anti-trust divestiture requirements arising from Teva’s acquisition of Allergan’s generics business.
Intas Pharmaceuticals, through its wholly owned subsidiary Accord Healthcare, has entered into a definitive agreement to acquire Actavis UK and Actavis Ireland from Teva Pharmaceutical Industries, for an enterprise value of £603 million payable in cash. The transaction is part of the European Commission’s anti-trust divestiture requirements arising from Teva’s acquisition of Allergan’s generics business.
• There is a compelling strategic fit which provides Accord with increased access to UK and Irish retail and hospital markets,
• Expands the UK manufacturing presence with the addition of the high quality Barnstaple site.
• More than doubles Intas’ pan-European operations, with pro-forma revenues exceeding $500 million.
• Intas will become a top 20 generics player globally.
• The transaction is due to complete in Q4 2016, subject only to regulatory approvals.
"This transaction represents a unique opportunity for Intas to build scale in UK & Ireland - adding to our market leading hospital franchise - and creates a strong platform for further European expansion" says Mr Binish Chudgar, Vice Chairman and Managing Director of Intas. "Through our subsidiary, Accord Healthcare, we have been operating successfully in Europe for more than a decade and this acquisition will make Accord a leading generics player in the UK market. We have a clear plan for the continuation and development of the Barnstaple site and the Actavis team and we look forward to welcoming them to the Intas Group. We are confident that the cultural alignment between Accord and Actavis UK & Ireland will ensure a smooth integration."
Actavis UK & Ireland is one of the leading suppliers of generic pharmaceuticals in both the UK and Irish markets and is made up of selected assets and operations across the respective markets. The company focuses on providing high quality generics to both pharmacies and wholesalers in the UK & Ireland through their strong employee base of over 600 staff. Actavis UK & Ireland is also supported by a strong manufacturing presence in the UK at its Barnstaple site which provides services both to Actavis and other third parties. The company generated over £250 million of sales in 2015.
"Together we have a great opportunity to build on the strong foundations of our respective organisations; we are excited to join the Intas/Accord family and look forward to an exciting future together" says Sara Vincent, Actavis SVP UK and Ireland.
This transaction further demonstrates Accord’s commitment to UK manufacturing, adding to its recent significant investment to reinstate a facility closed by Sanofi Aventis in Newcastle. The Barnstaple plant will become the company’s 4th UK site, ensuring Accord has one of the most extensive local supply chains to service pharmacies, hospitals and wholesalers across UK and Ireland and also into Europe.
Related News
-
News Patients vs Pharma – who will the Inflation Reduction Act affect the most?
The Inflation Reduction Act brought in by the Biden administration in 2022 aims to give better and more equitable access to healthcare in the USA. However, pharma companies are now concerned about the other potential costs of such legislation. -
News CPHI Podcast Series: What does the changing US Pharma market mean for industry and patients alike?
In this week's episode of the CPHI Podcast Series Lucy Chard, Digital Editor for CPHI Online is joined by James Manser to discuss the political and market changes in the US pharma field. -
News CPHI Barcelona Annual Report illuminates industry trends for 2024
The CPHI Annual Survey comes into it’s 7th year to report on the predicted trends for 2024. Over 250 pharma executives were asked 35 questions, with their answers informing the industry landscape for the next year, spanning all major pharma marke... -
News Which 10 drugs are open to price negotiation with Medicare in the USA?
The Centres for Medicare & Medicaid Services, under the Biden administration in the USA, has released a list of the 10 drugs that will be open to price negotiations as part of the new legislation under the Inflation Reduction Act (IRA). -
News EU Medical Devices Regulation causes unintended disappearances of medical devices for children, doctors state
Doctor groups and associations have appealed to the EU to correct the EU Medical Devices Regulation law that may cause unintended shortages of essential drug and medical devices for children and rare disease patients. -
News 10 Major Drug Approvals So Far in 2023
Last year, 37 novel drugs were approved by the FDA, this was a high number for such a category, and covered many fields including oncology, demonstrating how promising further research is, and how it is only continuing to build. To date, there are alre... -
News Detecting Alzheimer's disease with a simple lateral flow test
A novel rapid diagnostic test for early-stage Alzheimer's disease has been developed using a biomarker binder from Aptamer Group along with technology from Neuro-Bio, the neurodegenerative disease experts. -
News CPHI Podcast Series: outsourcing and manufacturing trends
Listen to the CPHI Podcast Series this June to hear Gil Roth of the PBOA speak with Digital Editor Lucy Chard about the biggest trends and topics to watch in pharma outsourcing and manufacturing at the minute.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance